C. Cook

发表

Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Journal of medicinal chemistry.

Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Bioorganic & medicinal chemistry letters.

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Journal of medicinal chemistry.

From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations

Rebecca E. Meadows, G. Currie, H. Emtenäs, 2021, Organic Process Research & Development.

Development of a Safe Continuous Manufacturing Route to 2-(4-Isopropyl-1H-1,2,3-triazol-1-yl)acetic Acid

H. Emtenäs, C. Cook, Staffan Karlsson, 2017 .

Exploration of a Nitromethane-Carbonylation Strategy during Route Design of an Atropisomeric KRASG12C Inhibitor.

Thomas O. Ronson, D. Buttar, K. Leslie, 2021, The Journal of organic chemistry.

Design, synthesis and evaluation of a novel series of spiroketals basedon the structure of the antibacterial gyrase inhibitor novobiocin

J. A. Grant, D. Timms, C. Cook, 1997 .

Synthetic and Chromatographic Challenges and Strategies for Multigram Manufacture of KRASG12C Inhibitors

H. Emtenäs, Anna-Carin C. Carlsson, C. Cook, 2021, Organic Process Research & Development.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.

A. Ferguson, L. Drew, W. Shao, 2020, Journal of medicinal chemistry.

Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of non-small cell lung cancer (NSCLC).

J. Breed, M. Anderton, Lyman J. L. Feron, 2019, Journal of medicinal chemistry.

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

J. Debreczeni, Lyman J. L. Feron, Michael Tonge, 2017, Journal of medicinal chemistry.

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.

G. Lamont, D. Buttar, S. Critchlow, 2022, Journal of medicinal chemistry.

General methods for the synthesis and late-stage diversification of 2,4-substituted 7-azaindoles

Rebecca E. Meadows, B. Barlaam, Bryan E. Roberts, 2016 .

The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.

Chris Davies, S. Gerhardt, David J. Milne, 2011, Bioorganic & medicinal chemistry letters.

Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.

B. Barlaam, P. Johnström, M. Schou, 2024, Journal of medicinal chemistry.